|
All Business Categories
|
Iomai Corp
Maryland, USA Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps int... Hemispherx Biopharma , Inc. PENNSYLVANIA, USA Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders... OXIS International , Inc. California, USA OXIS, which develops, manufactures, and markets products and technologies related to oxidative stress, currently offers more than 80 research products and two specialty compounds, ... Plexxikon Inc. California, USA Plexxikon is a leader in the discovery and development of novel small molecule pharmaceuticals to treat human disease. Plexxikon's proprietary Scaffold-Based Drug Discovery platfor... Pharmasset , Inc. New Jersey, USA Pharmasset is a clinical,stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is ... Texas, USA Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio of issued patents that covers six distinct classes of peptides, covering over 100,000 unique peptide sequen... NanoBio Corporation Michigan, USA NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented ... VIRxSYS Corporation Maryland, USA >VIRxSYS corporation is a private biotech company whose mission is to develop gene therapies using its proprietary lentiviral vector delivery system. The company is in Phase II cli... Nuvelo , Inc. California, USA Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nu... Trigen Ltd London, United Kingdom Trigen previously announced the successful completion of a Phase I dose escalation study on TGN 167 using a classical rapid release tablet formulation. Trigen is developing TGN 167...
First
Prev
[5]
[9]
[13]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
28
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[753]
[1470]
[2186]
Next
Last
|
